Find information on thousands of medical conditions and prescription drugs.

Orlistat

Orlistat (marketed as Xenical by Roche) is a drug designed to treat obesity. Its primary function is to prevent the absorption of dietary fats, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced calorie diet. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. Only trace amounts of orlistat are absorbed systemically, the primary effect is local lipase inhibition within the GI tract after an oral dose. The primary route of elimination is through the feces.

At the standard prescription dose of 120 mg three times daily before meals, orlistat prevents approximately 30% of dietary fat from being absorbed.

Efficacy

The amount of weight loss achieved with orlistat is variable. In 1 year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass. A significant amount of subjects regained the weight after they stopped using orlistat. Despite this cosmetically small effect, there was a 37% reduction in the incidence of Type 2 diabetes, a significant difference.

Side effects

The primary side effects of the drug are GI-related. Side effects were most severe within the first year of therapy. Because its main effect is to prevent dietary fat from being absorbed, the fat is excreted unchanged in the feces and so the stool may become oily or loose. Increased flatulence is also common. Bowel movements may become frequent or urgent. Rare occurrence of fecal incontinence have been seen in clinical trials. To minimize these effects, foods with high fat content should be avoided.

The absorption of fat-soluble vitamins are inhibited by the use of orlistat. A multivitamin tablet containing these vitamins (D, E, A and beta-carotene) should be taken once a day, at least 2 hours before or after taking the drug.

Contraindications

Xenical is contraindicated in:

  • Malabsorption
  • Reduced gallbladder function (e.g. after cholecystectomy)
  • Pregnancy and breastfeeding
  • Certain kidney problems

Availability

In most areas orlistat is available by prescription only. In 2004, a lower-dose version of the drug (60 mg compared to 120 mg for the prescription version) was released over the counter in Australia and New Zealand; the United States is expected to follow in the near future.

On January 23, 2006, a US Food and Drug Administration advisory panel voted 11 to 3 to recommend the approval of an OTC formulation of orlistat (planned to be marketed under the name "Alli" by GlaxoSmithKline). The proposed product will consist of 60 mg dosage units, similar to the OTC products available elsewhere.

Read more at Wikipedia.org


[List your site here Free!]


Orlistat improves weight management in obese adolescents
From American Family Physician, 10/15/05 by David Slawson

Clinical Question: Is orlistat (Xenical) effective for weight management in obese adolescents?

Setting: Outpatient (any)

Study Design: Randomized controlled trial (double-blinded)

Allocation: Concealed

Synopsis: Investigators identified 539 adolescents, 12 to 16 years of age, who met the criteria for obesity (a body mass index [BMI] of more than two units above the 95th percentile for age and sex). Participants were assigned randomly in a double-blind fashion to receive 120 mg of orlistat or placebo three times daily. All patients also received general recommendations for diet, exercise, and behavior modification. Persons blinded to treatment group assignment assessed outcomes. Follow-up for one year occurred for 98 percent of patients. Approximately two thirds of adolescents in each group completed the study.

The investigators performed a modified intention-to-treat analysis that included only patients with a baseline measurement and at least one measurement of effectiveness after baseline. At one year of follow-up, 26.5 percent of adolescents in the treatment group versus 15.7 percent in the placebo group had a 5 percent decrease in BMI, and 13.3 percent in the treatment group versus 4.5 percent in the placebo group had a 10 percent decrease in BMI (number needed to treat = 9; 95% confidence interval, 6 to 31 for both). Weight increased an average of 1.2 pounds with orlistat and 6.9 pounds with placebo (total cost per pound not gained = $374). Overall, BMI decreased by 0.55 in the orlistat group and increased by 0.31 in the placebo group (P = .001). Twelve patients (3.4 percent) taking orlistat and three patients (1.6 percent) taking placebo discontinued treatment because of adverse events, most often problems in the gastrointestinal tract. No major safety issues were reported.

Bottom Line: Orlistat, in combination with diet, exercise, and behavior modification, improves weight management in obese adolescents. No major safety issues were identified after one year, but further follow-up for sustained weight management and safety is important. (Level of Evidence: 1b)

DAVID SLAWSON, M.D.

Study Reference: Chanoine JP, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA June 15, 2005;293:2873-83.

Used with permission from Slawson D. Orlistat improves weight management in obese adolescents. Accessed online July 25, 2005, at: http://www.InfoPOEMs.com.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Orlistat
Home Contact Resources Exchange Links ebay